keyword
MENU ▼
Read by QxMD icon Read
search

oral antineoplastic

keyword
https://www.readbyqxmd.com/read/29430197/profile-of-buparlisib-and-its-potential-in-the-treatment-of-breast-cancer-evidence-to-date
#1
REVIEW
Carmen Criscitiello, Giulia Viale, Giuseppe Curigliano, Aron Goldhirsch
Alteration of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin signaling pathway is key for the growth and survival of several cancers, including breast cancer. In addition, dysregulation of PI3K signaling may contribute to resistance to several anticancer agents. PI3K inhibitors may, therefore, be effective as antineoplastic therapy. Buparlisib is a potent and highly specific oral inhibitor of the pan-class I PI3K family. Buparlisib specifically inhibits class I PIK3 in the PI3K/AKT kinase signaling pathway in an ATP-competitive manner, thus inhibiting the production of the secondary messenger phosphatidylinositol (3,4,5)-trisphosphate and activation of the PI3K signaling pathway...
2018: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/29389333/targeted-cancer-therapies-oral-health-care-implications
#2
Eleni Georgakopoulou, Justin Stebbing, Crispian Scully
BACKGROUND: Targeted treatments have been incorporated into oncology protocols, often with more traditional therapies, and are not totally free of adverse reactions, some of which affect the orofacial region. METHODS: The authors searched PubMed, the Cochrane Library, and the US Food and Drug Administration Approved Drug Products database to identify reported adverse effects of targeted agents in the orofacial region as well as other implications in oral health care...
February 2018: Journal of the American Dental Association
https://www.readbyqxmd.com/read/29375014/impact-of-a-formal-pharmacist-run-oral-antineoplastic-monitoring-program-a-pilot-study-in-an-adult-genitourinary-oncology-clinic
#3
Brette Conliffe, Lindsay Figg, Padmini Moffett, Leslie Lauterwasser, Laura Beth Parsons
Background In recent years, there has been a changing paradigm in the management of oncologic disease states from the use of intravenous therapies, requiring a visit to the infusion center or hospitalization, to new therapies that can be administered orally.1,2 Several publications have evaluated the role pharmacists may play in the initial prescribing of oral chemotherapy, however the impact of a formalized pharmacist follow-up program has not been well defined. This study evaluates the impact of a pilot pharmacist-run oral antineoplastic monitoring program...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29372342/determination-of-flutamide-and-two-major-metabolites-using-hplc-dad-and-hptlc-methods
#4
Nada S Abdelwahab, Heba A H Elshemy, Nehal F Farid
Flutamide is a potential antineoplastic drug classified as an anti-androgen. It is a therapy for men with advanced prostate cancer, administered orally after which it undergoes extensively first pass metabolism in the liver with the production of several metabolites. These metabolites are predominantly excreted in urine. One of the important metabolites in plasma is 4-nitro-3-(trifluoromethyl)phenylamine (Flu-1), while the main metabolite in urine is 2-amino-5-nitro-4-(trifluoromethyl)phenol (Flu-3). In this work the two metabolites, Flu-1 and Flu-3, have been synthesized, and then structural confirmation has been carried out by HNMR analysis...
January 25, 2018: Chemistry Central Journal
https://www.readbyqxmd.com/read/29306306/use-of-oral-antineoplastic-in-special-situations-in-a-third-level-hospital-real-life-results
#5
Carmen Garcia-Muñoz, Pedro Pablo Rodriguez-Quesada, José Miguel Ferrari-Piquero
OBJECTIVE: To analyse the effectiveness and safety of oral antineoplastic drugs  (ANEOs) that are authorized in special situations in a third-level hospital and to  compare the results obtained with the clinical evidence used for this  authorization. METHOD: Descriptive observational and retrospective study. We included all  adult patients who started treatment with ANEO in special situations during the  year 2016. We collected demographic, treatment-related and clinical variables  (overall survival (OS), progression-free survival (PFS))...
January 1, 2018: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/29298742/-multicentric-reticulohistiocytosis-is-a-rare-form-of-paraneoplasia
#6
Anna Maria Anderson, Tanja Todberg, Kristian Kofoed, Trine Zeeberg Iversen, Martin Andersen, Sofie Vetli Hjorth, Daniel El Fassi
A 59-year-old woman developed a rash and severe arthralgia, which primarily affected her fingers. She displayed digital arthritis and nodules on the hands, chest, face, and oral cavity. Blood samples were normal. Skin biopsies revealed histiocytic proliferation. The surface marker profile and clinical findings were consistent with multicentric reticulohistiocytosis, which may occur as a paraneoplastic phenomenon. On workup, she was diagnosed with an otherwise asymptomatic stage IVC fallopian tube cancer. She experienced little effect of prednisolone, but her condition improved on antineoplastic treatment...
January 1, 2018: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/29284479/acacia-hydaspica-r-parker-prevents-doxorubicin-induced-cardiac-injury-by-attenuation-of-oxidative-stress-and-structural-cardiomyocyte-alterations-in-rats
#7
Tayyaba Afsar, Suhail Razak, Khalid Mujasam Batoo, Muhammad Rashid Khan
BACKGROUND: The use of doxorubicin (DOX) an anthracycline antineoplastic agent is withdrawn due to its cardio-toxic side effects. Oxidative stress has been recognized as the primary cause of DOX induced cardiotoxicity. We have investigated whether polyphenol rich ethyl acetate extract of Acacia hydaspica (AHE) can attenuate doxorubicin-induced cardiotoxicity via inhibition of oxidative stress. METHODS: AHE was administered orally to rats once daily for 6 weeks at doses of 200 and 400 mg/kg b...
December 29, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/29197167/to-take-or-not-to-take-with-meals-unraveling-issues-related-to-food-effects-labeling-for-oral-antineoplastic-drugs
#8
Jiexin Deng, Satjit S Brar, Lawrence J Lesko
There has been controversy regarding whether bioavailability of certain oral oncology drugs should be maximized by taking these medications with food, irrespective of label instructions in the dosing and administration section. To provide insight into this controversy, we conducted an in-depth analysis for oral antineoplastic drugs approved by the Food and Drug Administration in 2000-2016 and identified important issues influencing food labeling decisions. Furthermore, a case study involving sonidegib, a drug approved for locally advanced basal cell carcinoma with a significant food effect on exposure, was used to demonstrate the consequences of failure to adhere to food label recommendations using drug-specific population pharmacokinetic and exposure-toxicity models...
December 2, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29176395/integrated-safety-summary-for-trifluridine-tipiracil-tas-102
#9
Alfredo Falcone, Atsushi Ohtsu, Eric Van Cutsem, Robert J Mayer, Michele Buscaglia, Johanna C Bendell, Scott Kopetz, Paul Bebeau, Takayuki Yoshino
Trifluridine/tipiracil, an oral treatment combining trifluridine (an antineoplastic thymidine-based nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor), led to significant improvement in overall survival in metastatic colorectal cancer (mCRC) patients refractory to standard therapy in the phase III RECOURSE trial. Here, we report an integrated summary of the safety of trifluridine/tipiracil. The main safety analysis includes integrated data from the RECOURSE and J003 studies (safety data group 2) of patients with refractory mCRC receiving trifluridine/tipiracil at the recommended starting dose: 35 mg/m twice daily for 5 days with 2 days' rest for 2 weeks, followed by a 14-day rest (one cycle)...
November 24, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29175466/photodynamic-therapy-for-treatment-of-oral-mucositis-pilot-study-with-pediatric-patients-undergoing-chemotherapy
#10
Vânia Cavalcanti Ribeiro da Silva, Fabiana Moura da Motta Silveira, Gabriela Souza Lima, Mônica Moreira Dias da Cruz, Arnaldo de França Caldas Júnior, Gustavo Pina Godoy
BACKGROUND: Oral mucositis has become a major factor dose-limiting toxicity of antineoplastic treatment. AIM: The aim of the present study was to evaluate the effect of photodynamic therapy (PDT) and low level laser therapy (LLLT) on the treatment of chemotherapy-induced mucositis in pediatric patients. METHODS: An open, controlled, and blind, randomized clinical trial was conducted with 29 patients, from 10 months to 18 years old, who were divided into two groups...
November 22, 2017: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/29138046/novel-cremochylomicrons-for-improved-oral-bioavailability-of-the-antineoplastic-phytomedicine-berberine-chloride-optimization-and-pharmacokinetics
#11
Manal A Elsheikh, Yosra S R Elnaggar, Dalia A Hamdy, Ossama Y Abdallah
Berberine chloride (BER) is an antineoplastic phytomedicine that combat non-Hodgkin lymphoma. BER suffers from low oral bioavailability due to p-glycoprotein efflux and first-pass metabolism. Lymphatic drug targeting recently gained a profound attention due to circumventing hepatic first-pass metabolism and targeting lymph diseases. Therefore, novel BER-loaded cremochylomicrons were elaborated to mitigate BER drawbacks and enhance its lymphatic targeting and bioavailability. Optimized cremochylomicron was prepared with 2...
November 11, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29119052/synergistic-anticancer-activity-of-a-novel-oral-chemotherapeutic-agent-containing-trifluridine-and-tipiracil-in-combination-with-anti-pd-1-blockade-in-microsatellite-stable-type-murine-colorectal-cancer-cells
#12
Norihiko Suzuki, Hiroshi Tsukihara, Fumio Nakagawa, Takashi Kobunai, Teiji Takechi
Trifluridine/tipiracil (FTD/TPI) is a combination of FTD, an antineoplastic thymidine-based nucleoside analog, and TPI, which acts to enhance the bioavailability of FTD in vivo. It is used to treat patients with unresectable advanced or recurrent colorectal cancer that is refractory to standard therapies. We investigated the anticancer activity of FTD/TPI combined with anti-mouse programed cell death 1 (PD-1) monoclonal antibody (mAb) against CMT-93 cells, which are microsatellite stable (MSS)-type murine colorectal cancer cells...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/29105806/the-orally-active-pterocarpanquinone-lqb-118-exhibits-cytotoxicity-in-prostate-cancer-cell-and-tumor-models-through-cellular-redox-stress
#13
Thiago Martino, Tarana A Kudrolli, Binod Kumar, Isis Salviano, André Mencalha, Marsen Garcia P Coelho, Graça Justo, Paulo R Ribeiro Costa, Kátia C Carvalho Sabino, Shawn E Lupold
BACKGROUND: The targeted induction of reactive oxygen species (ROS) is a developing mechanism for cancer therapy. LQB-118 is a pterocarpanquinone and ROS-inducing agent with proven antineoplastic activity. Here, LQB-118 efficacy and mechanism of activity, were examined in Prostate Cancer (PCa) cell and tumor models. METHODS: PC3, LNCaP, and LAPC4 PCa cells were applied. Dicoumarol treatment was used to inhibit quinone reductase activity. N-acetylcysteine (NAC) was applied as a ROS scavenger...
November 6, 2017: Prostate
https://www.readbyqxmd.com/read/29104720/dasatinib-induced-seborrheic-dermatitis-like-eruption
#14
Ryan R Riahi, Philip R Cohen
Dasatinib is an oral tyrosine kinase inhibitor approved for imatinib-resistant chronic myelogenous leukemia. It has been investigated in treating other neoplasms, including non-small-cell lung cancer and a subset of melanomas. Seborrheic dermatitis is characterized by erythematous patches or plaques with scaling typically affecting the external ear, glabella, hair-bearing areas of the face, nasolabial fold, and scalp. Antitumor agents are often associated with mucocutaneous side effects, including seborrheic dermatitis...
July 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/29090585/the-importance-of-pharmaceutical-care-in-oncologic-patients-undergoing-oral-antineoplastic-treatment-a-pilot-study-on-adherence-quality-of-life-and-perceptions-of-the-information-received
#15
Graziele Baldan Ferrari, Marília Berlofa Visacri, Júlia Coelho França Quintanilha, Gabriela Galhardo de Vito, Cristina Rosa Barbosa, Lara Paro Dias, Carmen Silvia Passos Lima, Patricia Moriel
No abstract text is available yet for this article.
October 1, 2017: American Journal of Medical Quality: the Official Journal of the American College of Medical Quality
https://www.readbyqxmd.com/read/29016351/ameliorative-effect-of-gallic-acid-on-doxorubicin-induced-cardiac-dysfunction-in-rats
#16
Temiday O Omóbòwálé, Ademola A Oyagbemi, Ayorinde M Folasire, Temitayo O Ajibade, Ebunoluwa R Asenuga, Olumuyiwa A Adejumobi, Olufunke E Ola-Davies, Orotusin Oyetola, Gana James, Adeolu A Adedapo, Momoh A Yakubu
BACKGROUND: The use of doxorubicin (DOX) as an antineoplastic agent has been greatly limited because of the myriad of toxic sequelae associated with it. The aim of this study was to assess the protective effects of gallic acid (GA) on DOX-induced cardiac toxicity in rats. METHODS: Sixty male rats (Wistar strain) were used in this study. They were divided into six groups (A-F) each containing 10 animals. Group A was the control. Rats in Groups B, C, and D were treated with DOX at the dosage of 15 mg/kg body weight i...
October 9, 2017: Journal of Basic and Clinical Physiology and Pharmacology
https://www.readbyqxmd.com/read/28987366/the-impact-of-gallic-acid-on-the-methotrexate-induced-kidney-damage-in-rats
#17
Halil Asci, Ozlem Ozmen, Hamit Yasar Ellidag, Bunyamin Aydin, Ercan Bas, Necat Yilmaz
Prolonged use of an antineoplastic agent methotrexate (MTX), can cause numerous side effects such as nephrotoxicity. The aim of this study was to examine the effects of MTX on kidneys and demonstrate the protective effects of gallic acid (GA). Twenty-four, male, rats distributed into three groups. Each groups consisted eight rats and only saline was administered to the control group. The MTX group received a single dose (20 mg/kg) MTX intraperitoneally. The MTX + GA group received same dose MTX and 100 mg/kg GA orally during the 7 days...
October 2017: Journal of Food and Drug Analysis
https://www.readbyqxmd.com/read/28969534/perioperative-management-of-female-hormone-medications
#18
Lynsey A Seim, Joan M Irizarry-Alvarado
BACKGROUND: No clear guideline exists for the management of female hormone therapy in the perioperative period. Besides oral contraceptives (OCPs), hormone medications have been prescribed to treat cancer, osteoporosis, and menopausal symptoms. Since the introduction of OCPs in the 1960s, the thromboembolic risk associated with these medications has been studied and alterations have been made in the hormone content. The continuation of hormone therapy in the perioperative period and its possible interactions with commonly used anesthetic agents are important information for all perioperative health care providers...
September 26, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28921641/pharmacokinetic-guided-dosing-of-new-oral-cancer-agents
#19
Catherine J Lucas, Jennifer H Martin
Generally, licensed drug-dosing recommendations for chemotherapy are based on results from clinical trials in which subjects are usually of relatively normal body size, middle-aged, and are relatively racially homogeneous, with minimal comorbidity and specific tumor characteristics. Very few nontrial patients meet these characteristics, resulting in clinical practice having to extrapolate dosing recommendations to the specific patient. There is insufficient research on the impact of obesity-associated physiological changes prevalent in patients with common cancers on standard pharmacokinetic and pharmacodynamic parameters...
October 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28912872/preclinical-trial-of-the-multi-targeted-lenvatinib-in-combination-with-cellular-immunotherapy-for-treatment-of-renal-cell-carcinoma
#20
Chengkuan Cai, Jingyuan Tang, Baixin Shen, Liucheng Ding, Yunpeng Shao, Zhengsen Chen, Yinchao Ma, Haoliang Xue, Zhongqing Wei
Lenvatinib is an oral, multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor β, RET and KIT. Cellular immunotherapy has the potential to be a highly targeted treatment, with low toxicity to normal tissues and a high capacity to eradicate tumor tissue. The present study assessed the safety, maximum tolerated dose (MTD) and preliminary antitumor activity of lenvatinib and cellular immunotherapy in a murine model of renal cell carcinoma (RCC)...
October 2017: Experimental and Therapeutic Medicine
keyword
keyword
86616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"